drugset / Trial / NCT04972188
A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of ZYIL1 Following Oral Administration in Healthy Volunteers
NaSingle-groupOpen-labelTreatment
Summary
ZYIL1 is a novel oral selective NLRP3 inflammasome inhibitor which prevents NLRP3-induced ASC oligomerization, thus inhibiting NLRP3 inflammasome pathway. ZYIL1 is expected to show benefit in patients demonstrating cytokine, like IL1β flare, including those exhibiting cytokine storm related to COVID-19 and other viral inflammatory diseases.
Timeline
- Start
- 2021-07-12
- Primary completion
- 2021-10-25
- Completion
- 2021-10-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Usnoflast | Small molecule | 12.5 mg | Oral |
Indications
No indication recorded.